D

Denali Therapeutics
D

DNLI

24.690
USD
0.47
(1.92%)
مغلق
حجم التداول
20,583
الربح لكل سهم
-3
العائد الربحي
-
P/E
-9
حجم السوق
3,553,424,897
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRVS
    -0.31000
    (-3.64%)
    8.21000 USD
    E
    ERYP
    -0.02670
    (-3.45%)
    0.70000 USD
    I
    IMVT
    -1.440
    (-5.13%)
    26.610 USD
    I
    ITCI
    -4.220
    (-4.82%)
    83.410 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    V
    VIR
    -0.63500
    (-7.35%)
    8.01000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    المزيد
الأخبار

العنوان: Denali Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brainpenetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.